[
  {
    "ts": "2026-01-06T01:00:00+00:00",
    "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China",
    "summary": "If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f",
    "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-010000397.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "1cf2541b-2656-3f6e-aef3-c23e978efb5f",
      "content": {
        "id": "1cf2541b-2656-3f6e-aef3-c23e978efb5f",
        "contentType": "STORY",
        "title": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China",
        "description": "",
        "summary": "If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f",
        "pubDate": "2026-01-06T01:00:00Z",
        "displayTime": "2026-01-06T01:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-010000397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-010000397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:13:34+00:00",
    "headline": "Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application",
    "summary": "Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...",
    "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-china-141334956.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9188d932-1254-3045-a2eb-54b28680c6a0",
      "content": {
        "id": "9188d932-1254-3045-a2eb-54b28680c6a0",
        "contentType": "STORY",
        "title": "Assessing Biogen (BIIB) Valuation After China Accepts LEQEMBI Subcutaneous License Application",
        "description": "",
        "summary": "Eisai and Biogen (BIIB) recently reported that Chinese regulators accepted a Biologics License Application for a subcutaneous version of LEQEMBI, a development that brings attention to Biogen’s current valuation and risk reward profile. See our latest analysis for Biogen. The LEQEMBI milestone lands at a time when Biogen’s 90 day share price return of 15.67% contrasts with a flat year to date share price picture and a mixed longer history, with a 1 year total shareholder return of 14.03% but...",
        "pubDate": "2026-01-06T14:13:34Z",
        "displayTime": "2026-01-06T14:13:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-china-141334956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-biogen-biib-valuation-china-141334956.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]